About LabGenius
LabGenius Therapeutics is a biotechnology company that has developed the EVA™ platform, a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties. The company combines human and machine intelligence to address the challenge that molecule performance is governed by a complex interplay of factors, making complex antibodies like multispecifics hard to engineer using conventional methods. LabGenius's platform is both modality and format-agnostic, but for its internal pipeline, the company focuses on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The EVA™ platform tightly integrates machine learning with automated functional screening in a closed loop, using proprietary ML-grade data from both functional and developability assays to fuel Multi-Objective Bayesian Optimisation. This approach enables the company to rapidly evaluate large numbers of multispecifics (>100,000 designs) for both function and developability, with each design-build-test-learn cycle taking less than 6 weeks. The platform can work with any modality including T-cell engagers, ADCs, NK-cell engagers, TCR-based engagers, agonists, cell therapies, radioconjugates, and multispecifics. LabGenius has raised over $75 million from top-tier venture capital firms and has established R&D partnerships with leading pharmaceutical companies including LG Chem.
Mission & Story
Mission
To advance the next generation of complex therapeutic antibodies
Founding Story
James Field, a protein engineer by training, founded LabGenius Therapeutics during his PhD studies at Imperial College London
Clinical Focus
Medical conditions and clinical areas addressed by LabGenius.
Who It Serves
Milestones & Awards
Recent Milestones
Research collaboration, option and license agreement with LG Chem to develop an AI/ML-designed tumour-targeting antibody (June 2026)
Key Partnerships
Social & Media
Follow on
Latest Updates
Article | The autonomous lab
Press release | LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
Press release | LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025
Article | Right On-Target: Developing Safe and Selective Multispecific T-Cell Engagers
Article | Programming biology: next-gen AI firms raise billions to design better medicines
Company Details
- Headquarters
- London, England, United Kingdom
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.